Allogeneic Stem Cell Transplantation to cure Acute Myeloid Leukemia in elderly patients

Pritesh Patel, Santosh Saraf, Damiano Rondelli


Outcomes for elderly patients with acute myeloid leukemia (AML) remain poor with standard therapies. Historically this age group has been excluded from treatment with allogeneic stem cell transplantation (allo-SCT) due to worries of excessive treatment related morbidity and mortality. However, transplantation outcomes have dramatically improved in the last decade due to the widespread use of less ablative conditioning regimens, improved supportive care, and improved patient selection based on prognostic tools such as the hematopoietic cell transplant specific comorbidity index. These have all led to an increasing acceptance of allo-SCT as a potential treatment modality in elderly patients with AML. This review addresses current strategies for patient selection and efficacy data for allo-SCT in elderly patients with AML.


Journal of Advances in Internal Medicine. 2012; 1(1): 43-49


allogeneic stem cell transplant; elderly; geriatric oncology

Full Text:



Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


  • There are currently no refbacks.

Copyright (c)

Indexed in Google Scholar, Ulrich’s International Periodical Directory, Summon discovery service, ProQuest, ICMJE, Genamics Gale/Cengage Learning, Thomson-Gale, JournalTOC, Science Central, EBSCOhost™, WorldCat, LibToc, Medical Journals Links, HINARI, Falvey Memorial Library (Villanova University),  Sciencegate, Research Bible